HSV-2 specific serology should not be offered routinely to antenatal patients.
The proposal to introduce antenatal screening for HSV has no evidence for a public or individual health benefit; indeed, it has the potential to increase anxiety for patients, with a minimal likelihood of reducing the risk of neonatal herpes infection. Antenatal screening of an essentially healthy population of women must be validated in settings of different rates of neonatal HSV infection and the purposes and limitations of screening clearly outlined. Identification of pregnant women at risk of acquiring genital herpes in pregnancy is also dependent upon being able to obtain the serostatus of the male sexual partner which will reduce the practical application of the test if both patient and partners need to be screened. We recommend that efforts to improve on the currently established mechanisms for reducing the morbidity of neonatal herpes, namely early diagnosis and prompt treatment, must take priority for resources over new and unevaluated screening programmes, such as routine testing of antenatal patients.